Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Am J Transplant. 2010 Oct;10(10):2331-40. doi: 10.1111/j.1600-6143.2010.03245.x. Epub 2010 Sep 3.
Despite continuous improvement in long-term survival, there is no knowledge about risk of bone health impairment and management strategies before and after intestinal transplantation. Therefore, 147 adults were retrospectively studied via chart review; 70 long-term survivors, 53 candidates and 24 recipients with longitudinal follow-up. Evaluation process included measurement of bone mineral density (BMD) and allied biochemical markers. Both long-term survivors and candidates showed low bone mass with lower (p < 0.05) z-scores at hip, femoral neck and spine. Vitamin D deficiency and secondary hyperparathyroidism were observed in both groups. Prevalence of osteoporosis was 44% among long-term survivors and 36% in candidates with age, BMD, duration of parenteral nutrition, type of immunosuppression and rejection being significant risk factors. Fragility fractures occurred at a higher (p = 0.02) rate among long-term survivors (20%) compared to candidates (6%). The longitudinal study documented acceleration (p = 0.025) of bone loss after transplantation with a decline of 13.4% (femoral neck), 12.7% (hip) and 2.1% (spine). Alendronate reduced (p < 0.05) but did not prevent bone loss. In conclusion, intestinal transplant recipients are at risk of osteoporosis secondary to bone loss before and after transplantation. Accordingly, current management includes comprehensive preventive measures with prompt therapeutic intervention utilizing intravenous bisphosphonates or subcutaneous human PTH.
尽管长期存活率不断提高,但对于肠移植前后骨健康受损的风险和管理策略仍知之甚少。因此,我们通过病历回顾对 147 名成年人进行了回顾性研究;70 名长期幸存者、53 名候选人和 24 名接受者进行了纵向随访。评估过程包括骨密度(BMD)和相关生化标志物的测量。长期幸存者和候选者均表现出低骨量,髋部、股骨颈和脊柱的 z 评分较低(p < 0.05)。两组均存在维生素 D 缺乏和继发性甲状旁腺功能亢进。长期幸存者的骨质疏松症患病率为 44%,候选者为 36%,年龄、BMD、肠外营养持续时间、免疫抑制类型和排斥反应是显著的危险因素。长期幸存者(20%)脆性骨折的发生率(p = 0.02)高于候选者(6%)。纵向研究记录了移植后骨丢失的加速(p = 0.025),股骨颈、髋部和脊柱分别下降了 13.4%、12.7%和 2.1%。阿仑膦酸钠可减少(p < 0.05)但不能预防骨丢失。总之,肠移植受者存在移植前后因骨丢失而导致骨质疏松症的风险。因此,目前的治疗方法包括采用静脉用双膦酸盐或皮下重组人甲状旁腺激素进行综合预防措施和及时的治疗干预。